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Abstract
Background: The incidence of cancer has been staying at a high level worldwide in recent years. With advances
in cancer diagnosis and therapy strategy, the survival rate of patients with cancer has been increasing, but the side
effects of these treatments, especially chemotherapy, are obvious even when the chemotherapy ceases. YH0618,
a prescription, has showed efficacy in reducing chemotherapy-induced toxicity through long clinical practice.
However, there is no scientific research exploring the effects of YH0618 in patients with cancer. Therefore, using a
randomized controlled trial, this study will explore the efficacy of YH0618 on ameliorating chemotherapy-induced
toxicity including dermatologic toxicity, myelosuppression, hepatotoxicity and nephrotoxicity and improving fatigue
in cancer patients who have completed chemotherapy.
Methods/design: This is a prospective assessor-blinded, parallel, randomized controlled trial. Patients with cancer
at any stage who have completed chemotherapy within two weeks will be randomly divided into group A
(YH0618) and group B (wait-list) using a 1:1 allocation ratio. The chemotherapeutic agents include taxanes or
anthracyclines. Subjects assigned to group A will receive YH0618 soup 6 days a week for 6 weeks and uncontrolled
follow-up for 6 weeks, while group B are required to wait for 6 weeks before receiving YH0618 intervention. The
primary outcome of this study is the incidence of protocol-specified grade ≥2 dermatologic toxicities graded by
NCI CTCAE Chinese version 4.0 and changes of fingernail color, face skin color and tongue color evaluated by the
L*a*b system within 6 weeks. There are some secondary outcomes associated with dermatologic toxicity including
fatigue and clinical objective examination.
Discussion: There are few scientific and safe methods in ameliorating chemotherapy-induced toxicity. The
proposed study may provide direct and convincing evidence to support YH0618 as an adjuvant treatment
for reducing chemotherapy-induced toxicity, which could be introduced into clinical settings.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-IOR-15006486. Registered on 21 May 2015.
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Background
According to the data from the WHO’s World Cancer
Report 2014, there are an estimated nearly 25 million
cancer cases that will occur over the next two decades
worldwide, a rise of 75 % [1]. Because of advances in
cancer diagnosis and treatment, the survival rate of
patients with cancer has been increasing, but the side
effects of these treatments, especially chemotherapy, are
obvious [2]. Chemotherapy, as a standard regimen, has
been used for treating cancers for 70 years. However, in
recent years, there is a controversy as to whether it
should continue to be used because it causes major side
effects, especially toxicity. However, as there is no better
regimen to replace chemotherapy, searching for safe and
effective ways to ameliorate chemotherapy-induced toxicity
has become an urgent issue in the cancer research area.
Chemotherapy-induced dermatologic toxicity is one of
the most obvious toxicities, and it can cause consider-
able cosmetic concern, pain, infection, and functional
impairment, and it further impact patients’ quality of
life, although it is rarely life-threatening [3, 4]. Its symp-
toms mainly include pruritus, bullous dermatitis, dry skin,
skin pain, paronychia, skin infection, acneiform rash,
alopecia, nail discoloration, and nail loss [5]. Low-grade
symptoms, such as nail ridging and nail discoloration, can
impact beauty and quality of life. Medium-grade symp-
toms like painful blisters and intense pruritus may also
interfere with treatment, resulting in dose reduction or
interrupting treatments. Some symptoms may even
continue after treatment ceases. Dermatologic toxicity is
a major side effect of more than 30 anticancer agents,
such as antimetabolites, hormonal agents, topoisomerase-
interacting agents, and taxanes; of these taxanes and
anthracyclines are the main chemotherapy drugs causing
these symptoms [6, 7]. Taxanes are microtubule-stabilizing
agents, including paclitaxel, docetaxel, and cabazitaxel,
which can stabilize GDP-bound tubulin in the micro-
tubule, therefore interrupting cell division and causing cell
death [8]. Anthracyclines are one of the most effective
chemotherapeutic drugs and are used to treat many can-
cers, like lymphomas, leukemias, breast cancer, uterine
cancer, ovarian cancer, and lung cancer. The mechanisms
of anthracyclines include four pathways. Anthracyclines
directly inhibit the synthesis of DNA and RNA by inser-
ting themselves in between nucleotides, thereby interfering
with replication and transcription [9]. They also inhibit
topoisomerase II, thereby generating reactive oxygen
species that damage DNA and cell membranes, or preven-
ting the relaxing of supercoiled DNA and thus blocking
DNA transcription and replication [10]. They can also
induct histone eviction from chromatin, deregulating DNA
damage response, epigenomes, and transcriptomes [11].
Recently, multiple options for reducing chemotherapy-
induced dermatologic toxicity have been investigated,
but there are no acknowledged and standard treatments.
Lacouture et al. [4] found the incidence of grade 2 skin
toxicities during the 6-week skin treatment period was
29 % in the pre-emptive group and 62 % in the reactive
group. A prospective study demonstrated that ice packs
could reduce the incidence of hand-foot syndrome in
patients treated with liposomal doxorubicin [5]. In con-
trast, no significant differences were determined between
hand conditions in terms of time to event, nor in terms of
toxicity, in cryotherapy and control groups in a random-
ized control trial [12]. Oral pyridoxine also failed to
prevent capecitabine-associated hand-foot syndrome [13].
Chemotherapy-induced myelosuppression, hepatotox-
icity, and nephrotoxicity are also common, and they are
significant complications affecting the treatment of
cancer patients. Moreover, from the view of Chinese
medicine, the liver and kidneys are the main organs
responsible for detoxification and purification of the
blood. Deficiencies of the liver and kidneys lead directly
to fatigue, which is also an obvious symptom of cancer
patients who just completing chemotherapy. So we be-
lieve that dermatologic toxicity and fatigue are a reflec-
tion of hepatotoxicity and nephrotoxicity.
Recent attempts to reduce toxicity by using individual
compounds have been unsatisfactory [14], and there is
also concern about whether using Chinese herbs will
cause hepatotoxicity and nephrotoxicity or interactions
with anticancer agents [15]; therefore, medical food is
the best choice. YH0618, a prescription, has showed effi-
cacy in reducing chemotherapy-induced toxicity through
long clinical practice. YH0618 consists of four medical
foods (such as black soybeans) which are recommended
by clinicians for patients with cancer, and all compo-
nents have a history of safe use in other foods. Besides,
each of the components possesses a distinct pharmaco-
logical profile, including removing free radicals in the
body, regulating the immune system, preventing cancer,
detoxifying, and enhancing taste, etc. [16–18]. Black
soybean, as the monarch drug in the prescription, has
been used for detoxification over the millennia in China.
Modern research has further explored its active com-
pounds and mechanisms in detoxification. Liao et al. [19]
found that a novel polysaccharide of black soybean could
improve 5-flurouracil- and irradiation-induced myelosup-
pression in animal experiments. Anthocyanins, which are
the main active compounds in the black soybean seed
coat, are water-soluble and possess significant anticancer
[20], antioxidation [21], liver-protective [22, 23], and
kidney-protective effects [24] in vitro and in vivo experi-
ments. Over long clinical observation, YH0618 soup has
been proved to be effective in reducing chemotherapy-
induced toxicity by clinical observation, but there is not
yet any scientific research exploring the effects of
YH0618 soup in patients with cancer. Therefore, this
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study will be conducted to further verify the benefits of
YH0618: the hypothesis is that YH0618 soup would
ameliorate chemotherapy-induced toxicity including
dermatologic toxicity, hematotoxicity, hepatotoxicity, and
nephrotoxicity in cancer patients who have completed
chemotherapy. Moreover, since little research has ex-
plored the role of medical food intervention in reducing
chemotherapy-induced toxicity, and YH0618 is a safe
medical food, the project will bring huge benefits to
patients with cancer. The YH0618 prescription has the
potential to become a standard alternative intervention
strategy in providing care to these patients.
Methods/design
Study design
This is a randomized controlled trial which aims at
determining whether YH0618 would be more effective
than the wait-list control conditions in ameliorating
chemotherapy-induced dermatologic toxicity, blood
system disorders, and hepatic and renal disorders and in
improving fatigue in cancer patients who have com-
pleted chemotherapy. To achieve this goal, a total of 236
patients with cancer at any stage who have completed
chemotherapy within 2 weeks will be recruited for the
study. The patients will be randomly divided into group
A (YH0618) and group B (wait-list) using a 1:1
allocation ratio, adhering to the Consolidated Standards
of Reporting Trials (CONSORT) statement [25] and the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) statement [26]. The measures
of clinical outcomes mainly include the grading of
dermatologic toxicity, skin color, nail color, tongue color,
and score of fatigue. Several biomarkers associated with
myelosuppression, hepatotoxicity, and nephrotoxicity in the
blood will also be measured. The flow chart of the study is
shown in Fig. 1, and the trial process is listed in Table 1.
The evaluation and data collected will be conducted at the
clinics of the School of Chinese Medicine, HKU.
Ethics
Ethical approval of the study protocol was obtained from
the Institutional Review Board of the University of Hong
Kong/Hospital Authority Hong Kong West Cluster
(HKU/HA HKW IRB, reference no. UW15-023). The trial
was registered in the Chinese Clinical Trials Registry:
ChiCTR-IOR-15006486. Patients will receive a detailed
information sheet and complete written consent forms.
The trial is managed by the School of Chinese Medi-
cine, HKU, and data will be supervised by the Data and
Safety Monitoring Board (DSMB). Study documents
(digital and hard copies) will be retained in a secure
location for 5 years after trial completion.
Fig. 1 Flow chart of the clinical trial
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Under the laws of Hong Kong, patients enjoy or may
enjoy rights for the protection of the confidentiality of
their personal data, such as those regarding the collection,
custody, retention, management, control, use (including
analysis or comparison), transfer in or out of Hong Kong,
non-disclosure, erasure and/or any way of dealing with or
disposing of any of their personal data in or for this study.
Clinical trial insurance will be provided to the subjects.
Subjects
A total of 236 eligible patients will be recruited through
advertisements. Inclusion criteria include: (1) patients with
cancer of any stage aged between 18–75; (2) completed
chemotherapy no more than 2 weeks ago; (3) received
chemotherapeutic agents containing taxanes or anthracy-
clines; and (4) a life expectancy of at least 6 months.
Exclusion criteria are: (1) subjects with a medical history
of dermatosis; (2) any treatment for detoxification within
3 months; (3) any severe mental disorders or history of
psychiatric illness or taking psychotropic drugs; (4) severe
lesions of liver or kidney; (5) pregnancy or potential preg-
nancy; (6) allergies to some specific foods, like black
soybean, etc. Eligible patients will be invited to participate
in this study after providing their written consent form.
All participants will be closely monitored in the study.
These patients are given open clinical treatment as an
additional safeguard.
Estimation of sample size
The primary outcome in this study is the proportion of
subjects with chemotherapy-induced dermatologic tox-
icity as measured by National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE)
specific grade ≥2. According to previous research, the
incidence of NCI CTCAE specific grade ≥2 after the
intervention is about 30 % [12]. Our pilot study showed
that about 10 % of subjects would have NCI CTCAE
specific grade ≥2 after taking the YH0618 soup; thus, the
difference in proportion of subjects with dermatologic
toxicity between the soup group and waiting-list control
group is 20 %. The difference in proportion between the
two groups will be examined by a Z-test. To achieve a
type I error alpha = 0.05 and power (1 – beta) = 90 %,
the minimal number of subjects needed in each group is
82. We estimated a 30 % attrition rate at the end of
follow-up; hence, a sample size of at least 118 in each
group (236 in total) is planned for this study.
Randomization and blinding
The research assistant will give each patient a unique
study number immediately after they complete the writ-
ten consent. A computer random digit (randomization
list) will be generated by a statistician not involved in
this study. Codes representing the two groups will be
printed on one A4 opaque paper, and then be put into a
envelope which is blotted out using double sided tape.
Table 1 Trial process chart






Process items 0 day 3 weeks 6 weeks 12 weeks
Patients
Inclusion and exclusion criteria ×
Informed consent ×
Demographics ×
Medical history × ×
Randomization and allocation concealment ×
Primary outcomes
Grading of dermatologic toxicity × × × ×
Objective skin, nail, and tongue color (L*a*b) × × × ×
Secondary outcomes
Fatigue measurement score × × × ×
Routine blood test (WBC, HGB, PLT) × × × ×
Liver function (ALT, AST, total protein, Alba) × × × ×
Renal function (Cr and BUN) × × × ×
Adverse events × × ×
Patients’ diary records Every day during the study
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The tape should be torn by the patients themselves just
after completing the baseline testing. Because this trial com-
pares the effects of the YH0618 group and the wait-list
group, it is not possible to blind the patients; thus, they
know which group they are in. However, the randomization
sequence and different groups will be kept hidden from the
practitioners, data collectors, and statisticians.
Intervention and control conditions
Prior to intervention, baseline data will be collected
including demographics, chemotherapy-induced derma-
tologic toxicity, skin color, nail color, tongue color, score
of fatigue, and the indexes of myelosuppression, hepato-
toxicity, and nephrotoxicity in the blood. After that,
participants assigned to group A will receive YH0618
soup 6 days/week for 6 weeks and uncontrolled follow-
up for 6 weeks, while group B are required to wait for
6 weeks and then receive YH0618 soup for 6 weeks.
There is no contraindication between YH0618 soup and
chemotherapy, because all the components are general
food which people often eat in their daily lives.
Outcome evaluation
Primary outcome
The primary outcome of this study is the incidence of
specific grade ≥2 dermatologic toxicities and changes of
nail color, skin color, and tongue color after 6 weeks of
intervention which will be graded by NCI CTCAE
Chinese version 4.0 and evaluated by the L*a*b system,
respectively.
Grading of dermatologic toxicity NCI CTCAE is com-
monly used to monitor and rate the severity of
chemotherapy-induced toxicity [27]. The CTCAE dis-
plays grades 1 through 5 with unique clinical descrip-
tions of severity for each adverse event. Protocol-defined
dermatologic toxicities include dry skin, pruritus, skin
ulceration, acneiform rash, maculopapular rash, skin
pain, skin hyperpigmentation, palmar-plantar erythrody-
sesthesia syndrome, scalp pain, alopecia, paronychia, nail
discoloration, nail ridging, and nail loss, which are elabo-
rated in Additional file 1. To reduce bias, the symptoms
will be recorded according to therapist diagnosis and
patient reports, but will not be graded in the presence of
the patients.
Skin, nail, and tongue color measurement In order to
evaluate the changes of skin, nail, and tongue color
objectively, L*a*b will be used. The L*a*b system, deter-
mined by the International Commission on Illumination
(CIE) in 1976, is a “gold standard” in assessing color. In
the CIELAB color space, values L*, a*, and b* form a
three-dimensional coordinate system by plotting at right
angles to one another [28]. Value L* represents light/
dark and extends from 0 (black) to 100 (white). Value a*
represents the red/green axis, and value b* represents
the yellow/blue axis. Recently, many methods are avail-
able to measure skin color, such as visual assessment,
rating scales, photography, reflectance spectroscopy, etc.
After analyzing the advantages and disadvantages of the
methods, we decided to adopt digital images in this
study. Digital image analysis has been used for more
than 15 years in medical imaging; it does not directly
contact the skin and therefore cannot disturb the mea-
surement of skin color (e.g., by blanching the skin). The
digital camera and environment like lighting source and
position, background, and distance between camera and
subject will be fixed. First, we will use a Canon® digital
camera to take pictures. In order to reduce interference
from the external environment, a calibration color chart
(Spyder CHECKR 24) will be adopted. Then, the Color
Sampler tools in Adobe PhotoShop Creative Suite 6
(CS6) will be used for digital image color analysis, which
can retrieve and record L*a*b* color values. We will
record the skin color of the forehead, right and left
cheeks, jaw, and dorsum of the right and left hands, the
nail color of ten fingernails, and tongue color.
Secondary outcomes
Fatigue measurement Fatigue is an obvious symptom
in patients with cancer who are receiving chemotherapy.
Fatigue will be measured by the Chinese version of
Functional Assessment of Chronic Illness Therapy-
Fatigue version 4 (FACIT-F), which can be used with
any tumor type [29]. It consists of 40 items scored on a
5-point Likert scale, ranging from 0 to 4. It has five
subscales including Physical Well-Being, Social/Family
Well-Being, Emotional Well-Being, Functional Well-
Being, and Additional Concerns. A total score will be
obtained by summing all subscale scores.
Clinical objective examination Myelosuppression:
There is evidence showing that cancer patients during
chemotherapy often have decreased white blood cells
(WBCs), hemoglobin (HGB), and platelets (PLTs) [30].
WBCs, also called leukocytes, can be divided into five
types, neutrophils, basophils, eosinophils, lymphocytes,
and monocytes, which are capable of defending the body
against foreign invaders and infectious diseases. The WBC
count is often regarded as an indicator of many diseases.
During chemotherapy, the decrease of WBC counts in
peripheral blood not only lead to fever, but also even sep-
ticemia and in severe cases, bleeding, which is one of the
reasons for complications after chemotherapy, but these
symptoms also disturb the process of chemotherapy,
further reducing the efficacy of treatments [31]. HGB is an
iron-containing oxygen-transport metalloprotein in the
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red blood cells of all vertebrates, which is essential for
metabolism. Its decrease may result in anemia; the symp-
toms include shortness of breath, palpitation of the heart,
and fatigability [32]. PLTs are derived from megakaryo-
cytes of the bone marrow and only exist in the blood of
mammals. The main function of PLTs is to stop bleeding.
Chemotherapy-induced significant reduction of PLTs will
cause thrombotic thrombocytopenic purpura charac-
terized by the presence of microangiopathic hemolytic
anemia, thrombocytopenic purpura, fever, renal abnor-
malities, and neurological abnormalities [33]. Therefore,
the changes of WBC, HGB, and PLT will be assessed.
Hepatotoxicity: Studies showed that many patients
with cancer experienced liver injury during chemothe-
rapy [34]. From the view of Chinese medicine, the liver
and kidneys are the main organs responsible for detoxifi-
cation. To evaluate liver function objectively, alanine
aminotransferase (ALT), aspartate transaminase (AST),
total protein, and albumin (Alba) will be measured.
Nephrotoxicity: Liver and kidney function are impor-
tant indicators in evaluating drug safety. Moreover,
based on the theory of homogeny of liver and kidney in
Chinese medicine, it is necessary to test kidney function.
In the testing of kidney function, injury to the kidney
can be exactly reflected by creatinine in the blood. The
concentration change of creatinine is determined by the
glomerular filtration rate, and only at a rate down to
one-third of normal will the creatinine increase signifi-
cantly [35]. In addition, blood urea nitrogen (BUN) is an
important indication of renal (kidney) health. Therefore,
creatinine (Cr) and BUN will be used as indexes to
assess nephrotoxicity.
All participants will be assessed before the interven-
tion (baseline), and 3, 6, and 12 weeks after intervention.
All YH0618 materials conform to Food and Environ-
mental Hygiene Department’s requirement for food
safety and achieve the certificate of quality. The packing
will be conducted at clinics of the School of Chinese
Medicine, HKU. A professional research assistant will
teach the subjects how to decoct the YH0618 soup, and
the specific intake, water amount, and decoction time
will be provided to each subject. These subjects will be
asked to complete the questionnaires, undergo blood
tests by themselves in hospitals, and send all testing
results. Quality and compliance to intervention will be
achieved by checking attendance records and the diary
of self-record kept by each participant. All outcome
assessors will be blinded to the intervention types of
participants.
Adverse events
All adverse events should be reported spontaneously by
patients or observed by assessors and will be recorded.
Adverse events will be graded on a five-point scale
(Mild, Moderate, Severe, Life threatening, Causing death).
When an adverse event occurs, the investigator will take
all necessary and appropriate measures to ensure the safety
of the patient. Any questions concerning adverse events
associated with the treatment will be reported on the study
case report form and sent to the Institutional Review
Board of the University of Hong Kong/Hospital Authority
Hong Kong West Cluster (HKU/HA HKW IRB).
Statistical analysis
Statistical analysis will be conducted by a statistician
using SPSS version 22.0. Analyses will be performed
based on intention-to-treat principles, and any missing
data in the follow up visits will be imputed using
multiple imputation.
Descriptive statistics will be used to summarize the
baseline demographics and clinical characteristics for
both groups. Missing values at follow-up visits or drop-
outs in the two groups will be assessed to identify any
potential bias.
For the primary outcomes, relative risk for the inci-
dence of dermatologic toxicities with grade ≥2, including
95 % CIs obtained via normal approximation to the
binomial distribution, will be analyzed for the two groups.
The changes in nail color and skin color from baseline to
6 weeks will be compared between the two groups by
independent sample t tests. Because participants will be
randomized into the intervention group or wait-list group,
little confounding is expected. However, potential con-
founding variables will be identified as those that differ
among treatment groups at baseline and are significantly
associated with outcomes. In case any potential con-
founders are identified, a logistic regression model and a
multiple linear regression model will be used to analyze
the binary and continuous outcomes, respectively.
In further analyses using measures at all time points, the
relative effectiveness of the interventions, including all
primary and secondary outcomes, will be assessed in
repeated measures mixed models, using the generalized
estimating equation (GEE) modeling method. The re-
peated measures regression models account for the corre-
lations between individual measurements when repeated
over time. The primary test of effect depends upon diffe-
ring patterns of change (slope) over time; thus, differences
in slope will be identified by significant interactions of
intervention group with time. If the interaction terms are
significant, then further analyses will use contrasts within
the models to compare groups at each time point and to
compare outcomes across time within each group.
Discussion
This is the first strict randomized controlled trial to
evaluate the effect of medical food on ameliorating
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chemotherapy-induced toxicity. The proposed study may
provide direct and convincing evidence to support YH0618
as an adjuvant treatment for reducing chemotherapy-
induced toxicity, which could be introduced into clinical
settings. Since little attention has been given to exploring
the role of medical food intervention in reducing
chemotherapy-induced toxicity, this study will provide
solid scientific evidence for international healthcare policy
makers to support the integration of alternative inter-
vention strategies in providing care to patients with cancer.
When considering that more and more cancer patients are
facing chemotherapy-induced side effects even after they
have completed chemotherapy, our achievements will pro-
vide a safe and effective way for reducing chemotherapy-
induced toxicity and improving their quality of life. The
objective assessments for chemotherapy-induced toxicity,
such as color index, are another important advantage in
this study.
However, the main potential limitation of this protocol
is that it is not double-blinded. A placebo would not be
used in this study, because it is difficult to make a
dietary placebo with the limited manpower and finances
at this stage. It is also more fair to the wait-list group, as
all of the subjects have opportunities to drink the
YH0618 soup. If the results are positive, we will further
compare the differences of the YH0618 soup and a
placebo in order to avoid psychological effects in the
future. Although the participants are not blinded, all of
the evaluators and statisticians are blinded.
Trial status
Recruitment started in July 2015, and the trial is expected
to be completed in June 2017.
Additional file
Additional file 1: Specific criteria for assessing chemotherapy-induced
dermatologic toxicity (NCI CTCAE). (DOCX 22 kb)
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